Sharpened Focus and Strategic Divestitures Underpin Buy Rating on Charles River Amid Valuation Discount

William Blair analyst Max Smock has reiterated their bullish stance on CRL stock, giving a Buy rating on February 20.

Max Smock has given his Buy rating due to a combination of factors tied to Charles River’s recent portfolio reshaping and valuation. He views the divestiture of the CDMO, cell solutions, and selected European discovery services assets as a strategically sound move that sharpens the company’s focus on its core preclinical offering, while also reducing exposure to areas he considers more susceptible to disruption from emerging AI tools.

He also notes that, despite a modest near-term revenue headwind from these sales, the transactions should enhance profitability in 2026 through margin expansion and incremental earnings per share. Combined with what he sees as a cautious full-year outlook, strengthening bookings, a healthier funding backdrop for biotech, and easing pricing and tariff pressures from large pharma clients, Smock believes there is room for the company to exceed expectations, especially given the current valuation discount to its long-term earnings multiple.

In another report released on February 20, TD Cowen also maintained a Buy rating on the stock with a $235.00 price target.

Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRL in relation to earlier this year.